Literature DB >> 22109951

Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.

Andrew F Shorr1, Marya D Zilberberg, Richard Reichley, Jason Kan, Alex Hoban, Justin Hoffman, Scott T Micek, Marin H Kollef.   

Abstract

BACKGROUND: Resistant organisms (ROs) are increasingly implicated in pneumonia in patients presenting to the emergency department (ED). The concept of healthcare-associated pneumonia (HCAP) exists to help identify patients infected with ROs but may be overly broad. We sought to validate a previously developed score for determining the risk for an RO and to compare it with the HCAP definition.
METHODS: We evaluated adult patients admitted via the ED with bacterial pneumonia (January-December 2010). We defined methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and extended-spectrum β-lactamases as ROs. The risk score was as follows: 4, recent hospitalization; 3, nursing home; 2, chronic hemodialysis; 1, critically ill. We evaluated the screening value of the score and of HCAP by determining their areas under the receiver-operating characteristic (AUROC) curves for predicting ROs.
RESULTS: The cohort included 977 patients, and ROs were isolated in 46.7%. The most common organisms included MRSA (22.7%), P. aeruginosa (19.1%), and Streptococcus pneumoniae (19.1%). The risk score was higher in those with an RO (median score, 4 vs 1; P < .001). The AUROC for HCAP equaled 0.62 (95% confidence interval [CI], .58-.65) versus 0.71 (95% CI, .66-.73) for the risk score. As a screening test for ROs, a score > 0 had a high negative predictive value (84.5%) and could lead to fewer patients unnecessarily receiving broad-spectrum antibiotics.
CONCLUSIONS: ROs are common in patients presenting to the ED with pneumonia. A simple clinical risk score performs moderately well at classifying patients regarding their risk for an RO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109951     DOI: 10.1093/cid/cir813

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

Review 1.  Update in respiratory infections 2011.

Authors:  Richard G Wunderink; Michael S Niederman
Journal:  Am J Respir Crit Care Med       Date:  2012-06-15       Impact factor: 21.405

2.  Clinical scoring for risk of resistant organisms in pneumonia: right idea, wrong interpretation.

Authors:  Natalie Bowman; Neela Goswami; Christopher K Lippincott; Michael J Vinikoor; William C Miller
Journal:  Clin Infect Dis       Date:  2012-06-05       Impact factor: 9.079

3.  "Does this patient have…" "Is this patient at risk for infection with multidrug resistant bacteria?"

Authors:  Cristina Vazquez Guillamet; Marin H Kollef
Journal:  Intensive Care Med       Date:  2015-11-10       Impact factor: 17.440

4.  What can be expected from antimicrobial de-escalation in the critically ill?

Authors:  Marin H Kollef
Journal:  Intensive Care Med       Date:  2013-11-19       Impact factor: 17.440

5.  Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.

Authors:  Alan E Gross; Trevor C Van Schooneveld; Keith M Olsen; Mark E Rupp; Thu Hong Bui; Elsie Forsung; Andre C Kalil
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

6.  Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia.

Authors:  S Kumagai; T Ishida; H Tachibana; Y Ito; A Ito; T Hashimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-10       Impact factor: 3.267

7.  Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia.

Authors:  Wesley H Self; Richard G Wunderink; Derek J Williams; Tyler W Barrett; Adrienne H Baughman; Carlos G Grijalva
Journal:  Acad Emerg Med       Date:  2015-05-20       Impact factor: 3.451

8.  Managing CAP in the ICU.

Authors:  Liapikou Adamantia; Makrodimitri Sotiria; Melaxroinidou Myrsini; Toumbis Michael
Journal:  Curr Infect Dis Rep       Date:  2015-11       Impact factor: 3.725

9.  Discordant minimum inhibitory concentration analysis: a new path to licensure for anti-infective drugs.

Authors:  Dean Follmann; Erica Brittain; John H Powers
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

10.  Evaluation of a pharmacy-driven methicillin-resistant Staphylococcus aureus surveillance protocol in pneumonia.

Authors:  Sarah Dunaway; Kara W Orwig; Zachary Q Arbogast; Zachary L Myers; James A Sizemore; Stephanie E Giancola
Journal:  Int J Clin Pharm       Date:  2018-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.